This week’s TDR Weekly Recap, presented by Flowhub, focuses on where federal cannabis reform stands now — and what the industry is watching next — alongside key company developments heading into 2026.On the policy front, the White House publicly included cannabis rescheduling as one of President Donald Trump’s first-year accomplishments following last month’s executive order directing the Department of Justice to complete the process of moving marijuana from Schedule I to Schedule III. While the order signals intent, rescheduling remains unfinished until the DOJ publishes a final rule. Industry attention is now squarely on timing, implementation, and how federal agencies follow through.In Florida, the adult-use cannabis campaign faces another uphill battle. Smart & Safe Florida is racing to meet signature requirements while polling continues to fall short of the state’s 60 percent threshold. Legal challenges, election audits, and renewed scrutiny from state officials underscore how difficult ballot initiatives remain in Florida’s regulatory environment.On the company side, Curaleaf released preliminary fourth-quarter results showing modest sequential growth, stable margins, and strategic exits from hemp and Missouri. The company continues to optimize its footprint while expanding selectively in core markets.Glass House Brands outlined accelerated 2026 expansion plans, including new greenhouse production coming online and preparations for potential international CBD and hemp opportunities tied to regulatory change.The episode also covers updates from Aurora Cannabis and Jushi Holdings, highlighting continued operational progress despite ongoing federal uncertainty.This recap breaks down what’s moving, what’s stalled, and why the next steps out of Washington matter for operators, investors, and the broader cannabis market.#CannabisRescheduling #TrumpCannabis #FederalCannabis #CannabisPolicy #TDRWeeklyRecap #Curaleaf #GlassHouseBrands #FloridaCannabis #CannabisStocks #FlowhubWant to see more Cannabis Reform videos?   • Why Trump’s Team Is Highlighting Cannabis ...     • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

What’s actually happening with cannabis research at the federal level — and why does it matter right now?In this episode of TDR Cannabis in Five, the focus turns to a quieter but critical development tied directly to federal cannabis reform. While much of the attention has been on marijuana rescheduling, a key deadline tied to cannabis research quietly passed without action. The U.S. Attorney General missed a congressionally mandated date to issue new rules that would clarify how researchers study Schedule I substances, including cannabis and psychedelics.That delay matters. For decades, federal drug policy has made legitimate cannabis research slow, expensive, and difficult to execute. Congress attempted to address that by directing the Department of Justice to create clearer, more workable registration and research guidelines. The goal was straightforward: reduce administrative friction and allow science to move forward.Instead, researchers are still operating under outdated and inconsistent rules — even as President Trump’s executive order last month directed agencies to complete the process of moving cannabis from Schedule I to Schedule III. The contrast highlights a growing gap between federal intent and federal execution.For scientists, universities, biotech firms, and cannabis operators watching rescheduling closely, this isn’t just procedural noise. Research access influences everything from medical validation and FDA pathways to investment confidence and long-term regulatory credibility.This episode breaks down why the missed deadline matters, how it fits into the broader rescheduling process, and what it signals about the pace of real change inside federal agencies as cannabis reform continues to evolve in 2026.#CannabisResearch #CannabisRescheduling #FederalCannabis #DOJ #PamBondi #DrugPolicy #CannabisScience #TDRCannabisInFive #MarijuanaPolicy #CannabisReformWant to see more Cannabis Reform videos?   • Why Trump’s Team Is Highlighting Cannabis ...     • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

This week’s TDR Weekly International Recap, presented by Prohibition Partners, takes a focused look at how global cannabis markets are evolving as regulation, consolidation, and compliance continue to shape the industry in 2026.With international attention firmly on Europe and Australia, several developments stand out. In Australia, a major medical cannabis merger is set to create one of the world’s largest vertically integrated operators, combining domestic manufacturing with large-scale European GMP cultivation. The deal highlights how scale, infrastructure, and supply reliability are becoming critical as patient demand expands across multiple regions.In Germany, cannabis reform remains politically complex. Lawmakers are divided over proposed restrictions on online prescribing and patient access, raising questions about how the country will balance medical oversight with accessibility in Europe’s largest medical cannabis market. These debates are increasingly relevant as Germany continues to navigate the regulatory distinction between hemp and pharmaceutical-grade medical cannabis.France remains in a holding pattern, with its long-awaited medical cannabis framework still unpublished. Despite delays, companies involved in the pilot program are already investing in pharmaceutical-grade infrastructure, positioning themselves ahead of a full commercial rollout once the regulatory path is finalized.The episode also revisits Germany, where legal developments involving High Tide’s (NASDAQ: HITI) subsidiary Remexian Pharma underscore the growing importance of compliance and regulatory clarity as investor scrutiny increases.#CannabisIndustry #GlobalCannabis #MedicalCannabis #EuropeanCannabis #AustraliaCannabis #GermanyCannabis #FranceCannabis #CannabisPolicy #CannabisMarkets #ProhibitionPartnersWant to see more Cannabis Reform videos?   • Why Trump’s Team Is Highlighting Cannabis ...     • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

In this episode of Trade To Black, presented by Flowhub, hosts Shadd Dales and Anthony Varrell break down one of the most important — and often misunderstood — debates in U.S. cannabis policy: youth access, regulation, and what the data actually shows.The conversation begins in Massachusetts, where state officials rejected a challenge to roll back marijuana legalization following allegations of deceptive petitioning tactics. Recent polling revealed that nearly half of voters who signed anti-legalization petitions felt misled, raising serious questions about how cannabis policy debates are framed and decided at the ballot level.From there, Kyle Sherman, CEO of Flowhub, joins the show to unpack what lawmakers often miss when discussing youth access. While opponents of legalization frequently claim regulated cannabis leads to higher youth usage, real-world data from states like Colorado, Washington, Oregon, and California shows the opposite — youth usage declines in regulated markets.Kyle explains why this happens at a systems level. This isn’t theory or philosophy — it’s infrastructure. From mandatory ID scanning and POS hard stops to audit trails, transaction logging, and compliance logic baked directly into retail software, regulated cannabis operates with safeguards the illicit market simply cannot replicate.The episode also covers the launch of The Great American Dispensary Tour – Maryland, Flowhub’s latest deep dive into how state-by-state regulation actually works on the ground.#CannabisPolicy #TradeToBlack #Flowhub #CannabisRegulation #YouthAccess #LegalCannabis #MarijuanaLegalization #CannabisTechnology #CannabisCompliance #CannabisIndustryWant to see more Cannabis Reform videos?   • Why Trump’s Team Is Highlighting Cannabis ...     • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

Is a regulated CBD program—potentially tied to Medicare—about to reshape who wins in U.S. cannabis?On the latest TDR Trade To Black, host Shadd Dales and co-host Anthony Varrell sit down with Micah Anderson, CEO of LEEF Brands (CSE: LEEF | OTCQB: LEEEF) for a grounded conversation about what could be coming next if Washington moves toward a structured, federally guided CBD framework.With cannabis reform back on the table following President Donald Trump’s executive order last month directing agencies to move rescheduling forward, the next question investors are starting to ask is: what does a regulated cannabinoid market actually look like when the government gets specific? That’s where a potential CBD framework—especially one connected to seniors, coverage, and medical channels—becomes a real storyline worth watching.The discussion focuses on what a “regulated CBD” market could actually look like in practice—distribution channels, compliance standards, insurance-style reimbursement dynamics, and why the rules (USDA vs FDA, cGMP expectations, contaminants, pesticide thresholds) will decide who’s truly positioned to participate.Micah explains why LEEF believes it has a practical head start: large-scale extraction infrastructure, earlier CBD experience through its Leaf Organics brand, and a pathway to activate hemp operations alongside cannabis capabilities under one roof in California—if state rules allow it. The conversation also digs into the economics—why regulated CBD could carry stronger margins than THC today, and why “full spectrum” matters if policymakers want real therapeutic outcomes.#CannabisNews #CannabisStocks #CannabisReform #Trump #DonaldTrump #ExecutiveOrder #CBD #Rescheduling #TradeToBlack #LEEFBrandsWant to see more Cannabis Reform videos?   • Why Trump’s Team Is Highlighting Cannabis ...     • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

Why is the White House now highlighting cannabis rescheduling as one of President Trump’s top accomplishments — and why does that matter heading into 2026?In this edition of TDR Cannabis in Five, host Shadd Dales breaks down the political significance behind the Trump administration publicly elevating marijuana rescheduling as a first-year achievement. This isn’t about re-litigating the policy itself. It’s about understanding why cannabis reform is being positioned as a political asset at this stage of the administration’s second term.Cannabis remains one of the few policy issues that consistently polls well across party lines, resonating with independents, younger voters, veterans, patients, and small business owners. By framing rescheduling around governance, medical access, economic participation, and regulatory clarity — rather than legalization — the White House is signaling a more strategic approach as the midterm cycle approaches.The episode also looks at the broader policy groundwork that helped make this moment possible, including years of advocacy around cannabinoids like CBD and the push to move cannabis further into the healthcare and institutional mainstream. That context matters when evaluating why federal leadership now appears more comfortable owning the issue publicly.Another key takeaway: when an administration labels something a major win, it ties its credibility to follow-through. That doesn’t remove legal or political hurdles, but it does reduce the likelihood of quiet delay.This is a snapshot of how cannabis policy has shifted from a political risk to a narrative tool — and what that says about where federal reform is heading next.#CannabisRescheduling #FederalCannabis #TrumpAdministration #CannabisPolicy #ScheduleIII #USCannabis #PoliticalStrategy #CannabisReform #HealthcarePolicy #TDRCannabisWant to see more Cannabis Reform videos?   • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

Trade to Black presented by Flowhub returns with hosts Shadd Dales and Anthony Varrell for a timely conversation focused on where U.S. cannabis policy, capital markets, and regulatory expectations stand right now. Joining the show is Marc Cohodes, veteran investor, former hedge fund manager, and longtime participant in the cannabis sector.It has now been more than a month since President Trump signed the executive order directing cannabis rescheduling, yet the industry is still waiting on formal action from Attorney General Pam Bondi. Marc breaks down what that delay could signal, how policymakers in Washington are viewing the timeline, and whether the lack of movement itself is creating unintended consequences across the market.The discussion also looks at how Big Pharma and Big Alcohol are positioning themselves as the possibility of Schedule III becomes more concrete, and what that could mean for operators, competition, and long-term market structure. Marc shares his perspective on whether uplisting becomes more realistic post-rescheduling, how lawmakers are thinking about FINRA, and whether changes to federal classification could reduce the importance of SAFER Banking as a near-term catalyst.The conversation also touches on Glass House Brands (OTCQX: GLASF) following the company’s newly announced 2026 expansion strategy, along with Marc’s view on how scaled operators may be positioned as the regulatory backdrop continues to shift. Finally, the group discusses Sara Carter’s recent appointment and her public push to see rescheduling finalized, and whether there appears to be meaningful alignment behind the scenes.A candid, timely discussion focused on signals—not speculation.#CannabisRescheduling #ScheduleIII #TradeToBlack #CannabisInvesting #CannabisStocks #FederalCannabis #BigPharma #BigAlcohol #GlassHouseBrands #FlowhubWant to see more Cannabis Reform videos?   • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

What does real capital flow actually look like in the U.S. cannabis industry right now — beyond market narratives and headlines?In this edition of TDR Cannabis in Five, host Shadd Dales walks through newly released funding data from FundCanna to better understand how cannabis operators are accessing and deploying capital as the industry moves deeper into 2026.The dataset spans thousands of applications across dozens of U.S. states and offers a grounded look at where demand remains steady, where it has moderated, and how capital usage has evolved across the sector. Rather than pointing to stress or contraction, the numbers suggest a shift toward more deliberate and targeted financing.Funding activity is spread across nearly every vertical — including vertically integrated operators, retail, cultivation, manufacturing, hemp, and ancillary services. Average deal sizes remain measured, terms are structured, and capital is largely being used for core operational needs such as inventory, payroll, and working capital.Geographically, businesses in 43 states have accessed funding, reinforcing that financing demand extends well beyond legacy markets. Even in a year marked by relatively flat macro growth, capital continues to support day-to-day operations and incremental expansion.Taken together, the data points to an industry that is operating with greater financial discipline. Capital is still moving, but in more controlled amounts and with clearer use cases — reflecting a more mature phase of development under continued federal constraints.#CannabisIndustry #CannabisFinance #CannabisInvesting #FundCanna #CannabisCapital #CannabisOperators #CannabisMarkets #Cannabis2026 #CannabisBusiness #TDRCannabisWant to see last week's recap?   • Hemp Politics, State Legalization, and Cap...  Want to see more Cannabis Reform videos?   • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

One month after the White House executive order directing a fast-track push to move cannabis to Schedule III, host Anthony Varrell is joined by Michael Bronstein (President, ATACH — American Trade Association for Cannabis and Hemp) for a ground-level debrief on what’s actually changed—and what hasn’t—since the announcement.This episode zeroes in on two major developments shaping the next phase of U.S. cannabis policy: the confirmation of Sara Carter as the nation’s new “Drug Czar” (ONDCP Director) and Virginia’s latest move to finally bring an adult-use retail market online—including a newly filed bill that would establish the legal framework for licensed cultivation, processing, testing, and sales.Topics we coverSchedule III cannabis rescheduling: what the executive order does, what it doesn’t, and why the process matters more than the headlineHow rescheduling could impact research, compliance, taxes (280E), banking optics, and operator strategySara Carter’s appointment: what her leadership at ONDCP could mean for enforcement priorities, public health messaging, and the cannabis industry narrativeVirginia adult-use cannabis: the latest bill push to launch regulated sales, key provisions, and what the political runway looks like in 2026The broader chessboard: federal agencies, state rollouts, hemp-derived cannabinoids, and the next catalysts investors and operators are watching#CannabisNews #TradeToBlack #Flowhub #CannabisPolicy #CannabisRescheduling #AdultUseCannabis #MarijuanaMoment #CannabisInvesting #CannabisIndustry #CannabisMarketsWant to see last week's recap?   • Hemp Politics, State Legalization, and Cap...  Want to see more Cannabis Reform videos?   • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...

What happens when cannabis policy, hemp politics, and capital markets all collide in the same week?In this episode of TDR Weekly Recap, presented by Flowhub, host Shadd Dales breaks down a wide-ranging week for the cannabis industry — from federal contradictions around hemp and THC, to renewed adult-use momentum in key U.S. states, and meaningful business developments across North America and Europe.The show starts with a surprising moment from Joe Rogan and Senator Rand Paul, who laid bare the political irony behind the federal crackdown on hemp-derived THC — including how parts of the regulated cannabis industry may have supported restrictions that ultimately limit interstate competition.From there, attention turns to state-level reform. Virginia moves closer to resolving its long-standing retail limbo, Florida ramps up one of the most expensive cannabis ballot campaigns in U.S. history backed by Trulieve Cannabis Corp. (CSE: TRUL | OTCQX: TCNNF), and Pennsylvania remains stuck debating who should control cannabis sales — not whether legalization should happen.On the business side, the episode covers Village Farms International (NASDAQ: VFF) expanding regulated products in the Netherlands, Glass House Brands (OTCQX: GLASF | CSE: GLAS.A) advancing AI-driven cultivation research with UC Berkeley, Verano Holdings (CSE: VRNO | OTCQX: VRNOF) launching a new pre-roll brand while extending its credit facility, Aurora Cannabis (NASDAQ: ACB | TSX: ACB) progressing disease-resistant genetics, and Incannex Healthcare (NASDAQ: IXHL | ASX: IHL) earning international recognition for clinical trial innovation.This isn’t about hype — it’s about how policy, capital, and execution are reshaping cannabis in real time.#CannabisNews #TDRWeeklyRecap #CannabisPolicy #HempTHC #AdultUseCannabis#CannabisStocks #CannabisIndustry #Flowhub #CannabisInvesting #GlobalCannabisWant to see more Cannabis Reform videos?   • Alcohol Rules Change While Cannabis Stays ...     • Proposed Hemp Extension Faces Ongoing Unce...     • The $4 Billion Problem Facing U.S. Cannabi...  Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook:   / thedalesreport  Twitter:   / thedalesreport  Instagram:   / dalesreport  LinkedIn:   / the-dales-report  Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...